Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer

S Ogino, GJ Kirkner, K Nosho, N Irahara, S Kure… - Clinical Cancer …, 2008 - AACR
S Ogino, GJ Kirkner, K Nosho, N Irahara, S Kure, K Shima, A Hazra, AT Chan, R Dehari…
Clinical Cancer Research, 2008AACR
Abstract Purpose: Cyclooxygenase-2 (COX-2; PTGS2) is considered to play an important
role in colorectal carcinogenesis and is often up-regulated in colon cancers. However,
previous data on the influence of COX-2 expression on patient outcome have been
conflicting. Experimental Design: Using 662 colon cancers (stage I-IV) in two independent
prospective cohorts (the Nurses' Health Study and the Health Professionals Follow-up
Study), we detected COX-2 overexpression in 548 (83%) tumors by immunohistochemistry …
Abstract
Purpose: Cyclooxygenase-2 (COX-2; PTGS2) is considered to play an important role in colorectal carcinogenesis and is often up-regulated in colon cancers. However, previous data on the influence of COX-2 expression on patient outcome have been conflicting.
Experimental Design: Using 662 colon cancers (stage I-IV) in two independent prospective cohorts (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected COX-2 overexpression in 548 (83%) tumors by immunohistochemistry. Cox proportional hazards models were used to compute hazard ratios (HR) of colon cancer-specific and overall mortalities, adjusted for patient characteristics and related molecular events, including the CpG island methylation phenotype, microsatellite instability, and p53, CIMP, KRAS, and BRAF mutations.
Results: During follow-up of the 662 cases, there were 283 deaths, including 163 colon cancer-specific deaths. Patients with COX-2-positive tumors showed a trend towards an inferior colon cancer-specific mortality [HR, 1.37; 95% confidence interval (95% CI), 0.87-2.14], which became significant after adjusting for tumor stage and other predictors of clinical outcome (multivariate HR, 1.70; 95% CI, 1.06-2.74; P = 0.029). Notably, the prognostic effect of COX-2 expression might differ according to p53 status (Pinteraction = 0.04). Compared with tumors with both COX-2 and p53 negative, COX-2-positive tumors were significantly associated with an increased cancer-specific mortality (multivariate HR, 2.12; 95% CI, 1.23-3.65) regardless of p53 status. A similar trend was observed when overall mortality was used as an outcome.
Conclusion: COX-2 overexpression is associated with worse survival among colon cancer patients. The effect of COX-2 on clinical outcome may be modified by p53 status.
AACR